Acral Peeling Skin Syndrome: Two Unusual Cases and the Therapeutic Potential of Botulinum Toxin
DOI:
https://doi.org/10.2340/actadv.v104.24305Keywords:
Acral Peeling Skin Syndrome, Genetics, Clinical findings, Botulinum toxinAbstract
Abstract is missing (Short communication)
Downloads
References
Cañueto J, Bueno E, Rodríguez-Diaz E, Vicente-Díaz MA, Álvarez-Cuesta CC, Gonzalvo-Rodríguez, et al. Acral peeling skin syndrome resulting from mutations in TGM5. J Eur Acad Dermatol Venereol 2016; 30: 477-480.
https://doi.org/10.1111/jdv.12863 DOI: https://doi.org/10.1111/jdv.12863
Muttardi K, Nitoiu D, Kelsell DP, O'Toole EA, Batta K. Acral peeling skin syndrome associated with a novel CSTA gene mutation. Clin Exp Dermatol 2016; 41: 394-398.
https://doi.org/10.1111/ced.12777 DOI: https://doi.org/10.1111/ced.12777
Acral peeling skin syndrome. Genetic and Rare Diseases Information Center. Updated February 2023 [accessed September 2023]. Available from: https://rarediseases.info.nih.gov/diseases/12863/acral-peeling-skin-syndrome.
Kiritsi D, Cosgarea I, Franzke CW, Schumann H, Oji V, Kohlhase J, et al. Acral peeling skin syndrome with TGM5 gene mutations may resemble epidermolysis bullosa simplex in young individuals. J Invest Dermatol 2010; 130: 1741-1746.
https://doi.org/10.1038/jid.2010.23 DOI: https://doi.org/10.1038/jid.2010.23
Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015; 17: 405-424.
https://doi.org/10.1038/gim.2015.30 DOI: https://doi.org/10.1038/gim.2015.30
Vahlquist A, Tasanen K. Epidermolysis bullosa care in Scandinavia. Dermatol Clin 2010; 28: 425-427.
https://doi.org/10.1016/j.det.2010.02.018 DOI: https://doi.org/10.1016/j.det.2010.02.018
Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alföldi J, Wang Q, et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature 2020; 581: 434-443. DOI: https://doi.org/10.1530/ey.17.14.3
https://doi.org/10.1038/s41586-020-2308-7 DOI: https://doi.org/10.1038/s41586-020-2308-7
Sprecher E. Epidermolysis bullosa simplex. Dermatol Clin 2010; 28: 23-32.
https://doi.org/10.1016/j.det.2009.10.003 DOI: https://doi.org/10.1016/j.det.2009.10.003
Nawrocki S, Cha J. Botulinum toxin: pharmacology and injectable administration for the treatment of primary hyperhidrosis. J Am Acad Dermatol 2020; 82: 969-979.
https://doi.org/10.1016/j.jaad.2019.11.042 DOI: https://doi.org/10.1016/j.jaad.2019.11.042
Swartling C, Karlqvist M, Hymnelius K, Weis J, Vahlquist A. Botulinum toxin in the treatment of sweat-worsened foot problems in patients with epidermolysis bullosa simplex and pachyonychia congenita. Br J Dermatol 2010; 163: 1072-1076.
https://doi.org/10.1111/j.1365-2133.2010.09927.x DOI: https://doi.org/10.1111/j.1365-2133.2010.09927.x
Published
How to Cite
License
Copyright (c) 2024 Anna-Lotta Stjernbrandt, Magnus Burstedt, Emma Holmbom, Alexander Shayesteh
This work is licensed under a Creative Commons Attribution 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
